SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

PURPOSE: Androgen deprivation therapy (ADT), an important treatment for advanced prostate cancer, is highly variable in its effectiveness. We hypothesized that genetic variants of androgen transporter genes, SLCO2B1 and SLCO1B3, may determine time to progression on ADT. PATIENTS AND METHODS: A cohor...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Yang, Ming, Xie, Wanling, Mostaghel, Elahe, Nakabayashi, Mari, Werner, Lillian, Sun, Tong, Pomerantz, Mark, Freedman, Matthew, Ross, Robert, Regan, Meredith, Sharifi, Nima, Figg, William Douglas, Balk, Steven, Brown, Myles, Taplin, Mary-Ellen, Oh, William K., Lee, Gwo-Shu Mary, Kantoff, Philip W.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2011
Предметы:
Original Reports
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3138634/
https://ncbi.nlm.nih.gov/pubmed/21606417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.2405
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы